The company aims to scale production of its genetically modified pig organs for human transplantation. Rendering courtesy McCord

Maryland-based United Therapeutics Corp. has opened a new 77,448-square-foot facility to manufacture xeno-organs in Northeast Houston’s growing biotech hub, Generation Park.

The new Houston location is United Therapeutics’ third Designated Pathogen-Free (DPF) site, named for transplant pioneers Dr. Bartley P. Griffith and Dr. Robert A. Montgomery. The company says the new facility will enable it to scale commercial production of its xeno-organs once they receive regulatory approval.

An existing DPF facility in Virginia is supporting clinical trials for the xeno-organs, and a third site in Minnesota will also focus on commercialization with the Houston site, according to the company.

Xeno-organs are organs taken from a non-human animal source and transplanted, implanted or infused into a human recipient.

Currently, United Therapeutics is advancing clinical trials to support a Biologics License Application with the U.S. Food and Drug Administration for its investigational-stage xenotransplantation, UKidney, UThymoKidney and UHeart products. The products all involve working with the genes from humans and pigs.

In 2025, Chron.com reported the company was working to construct an estimated $96 million facility to breed genetically engineered animals. Head of investor relations at United Therapeutics Dewey Steadman told the Houston Business Journal in 2025 that the pigs’ DNA will be edited. In November 2024, a 53-year-old woman in Alabama received a transplanted kidney from UKidney that had 10 gene edits. She had the transplant removed in April 2025, after her body rejected it.

The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility requires a “strictly controlled, biosecure barrier environment, including air filtration, filtered water, filtered feed supplies, and state-of-the-art decontamination entryways,” according to the company. Being pathogen-free means it includes calibrated air and water conduits to support the transplantability of xenograft products and to prevent contamination. For energy considerations, the building also features solar arrays.

“With our third xenograft production facility now open and clinical trials underway, United Therapeutics is moving closer to its goal of providing transplantable organs to the people who need them,” Martine Rothblatt, chairperson and CEO of United Therapeutics, said in a news release. “It is fitting that this facility is named for Dr. Griffith and Dr. Montgomery, whose first-in-human surgeries turned xenotransplantation from a theoretical possibility into a clinical reality.”

The facility, which wrapped construction in August, is located at 11848 Common Dock Dr. in Generation Park, which will house manufacturing sites for pharmaceutical heavyweights Bristol Myers Squibb and Eli Lilly. Last fall, Eli Lilly tapped Generation Park for its $6.5 billion manufacturing plant, and Bristol Myers Squibb made a $2.3 billion investment in August to bring its state-of-the-art site to the master-planned commercial district.

The site will manufacture Lilly's first synthetic oral GLP-1 medication and other advanced therapeutics. Photo via gov.texas.gov

Eli Lilly breaks ground on $6.5B pharmaceutical factory in Houston

lilly lands

Leading pharmaceutical company Eli Lilly broke ground today, Sept. 21, on its $6.5 billion manufacturing site at Houston's Generation Park.

The 236-acre, state-of-the art factory is expected to come online in 2030 and will manufacture Foundayo, the company's first synthetic oral GLP-1 medication, as well as other advanced therapeutics.

"We are thrilled to break ground on our latest ‘medicines made in America’ site in the great state of Texas," David Ricks, Lilly chair and CEO, said in a prepared statement. "This $6.5 billion investment will help change the game for tens of millions of people suffering from overweight, obesity and its consequences like diabetes. We will make and ship Lilly’s latest products from Texas to people here at home and around the world.”

Houston was up against more than 300 locations in the U.S. for the factory, as part of Lilly’s $50 billion investment in domestic medicine production that has launched 10 manufacturing sites since 2020. Lilly first announced Houston had been selected for the site last September.

Photo via gov.texas.gov

As Abbott mentioned, the site is expected to create hundreds of jobs, and will hire engineers, scientists, operations personnel and lab technicians once up and running. It will create 4,000 construction jobs while being built.

In an effort to support workforce development, Lilly also announced a $12.5 million commitment to Houston's San Jacinto College in addition to a $2.5 million charitable donation to the San Jacinto College Foundation. The funding will go toward hands-on training, equipment and facilities to support future technicians, operators, maintenance professionals, and other manufacturing talent, according to Lilly. The charitable donation will fund scholarships for students.

"This relationship will build a strong, sustainable talent pipeline for Lilly while creating meaningful, high-demand career opportunities across our region,” Brenda Hellyer, chancellor of San Jacinto College, said in the release.

"When you invest in a place like Houston, you invest in its people first," Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations, added. "This facility will run on the talent of this community, powered by our relationship with San Jacinto College. We're hiring across the greater Houston area to help residents build careers close to home."

Rendering courtesy Eli Lilly

Lilly previously said it chose Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, because of factors such as financial incentives, access to utilities and transportation and the region’s business-friendly environment. Generation Park is home to campuses for San Jacinto College and Lone Star College.

Since Lilly first announced plans for the site, another fellow pharma giant has made plans to move into Generation Park. Bristol Myers Squibb Co. announced last month that it would build a $2.3 billion factory in the district. The site is expected to manufacture small molecule, biologic and antibody-drug conjugates and will also come online around 2030. Read more here.

The report considered patents, NIH funding, lab space, venture capital investments and the number of jobs. Photo via Pexels

Houston named the No.1 emerging city for biopharma in inaugural report

Biopharma Leader

Houston is ranked No.1 on the first-ever Next 10 U.S. Biopharma Clusters report published by Genetic Engineering & Biotechnology News (GEN).

The report, which ranks the best emerging hubs for life science activities, considered patents, NIH funding, lab space, venture capital investments, and the number of jobs in regions in cities, states and “clusters” across the U.S. GEN touts Houston as the top city for the biopharma industry due to a surge in funding, job creation, medical innovations and startup success.

Here’s how Houston ranked in the report’s different categories;

  • No. 1 for NIH funding with 2,262 awards totaling more than $1.25 billion
  • No. 2 for emerging regions for jobs, with 28,000 jobs
  • No. 2 for lab space, with roughly 8 million square feet in the market
  • No. 6 for patents, with 2,760 patent families

According to BioHouston chairman Jeff Wade, Houston secured half a billion dollars in venture capital funding in 2025 and 2026 to date.

The report called out major biopharm news out of Houston in the last few months, including Bristol Myers Squibb selecting Houston for its $1 billion, 600,000-square-foot manufacturing site and Eli Lily selecting Houston for its $6.5 billion, 236-acre manufacturing site. Both facilities will be located within Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston.

Houston startups like CrossBridge Bio and Duracyte were also mentioned in the report. CrossBridge, which develops antibody-drug conjugates for cancer, was acquired by Eli Lily in April for $300 million. Duracyte, a “living pharmacy” company, was launched out of Rice University’s biotech venture studio RBL LLC this spring and is backed by up to a $45 million Advanced Research Projects Agency for Health (ARPA-H) award.

The startup is working to commercialize its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR) technology, a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time.

“There’s a lot of great talent, but the unique advantage that we have is we are able to benefit from a lot of unique clinical infrastructure and clinician insights,” Omid Veiseh, Duracyte co-founder and managing partner of RBL LLC, told GEN. “There are a lot of clinicians here who are eager to partner on investigator-initiated trials.”

The report also touted Houston’s Texas Medical Center, home to the University of Texas MD Anderson Cancer Center and Baylor College of Medicine, and international partnerships like the recently expanded TMC Korea BioBridge.

Other cities to make the list include:

  • No. 2 Minneapolis-St. Paul
  • No. 3 Denver-Boulder
  • No. 4 St. Louis
  • No. 5 Dallas-Fort Worth

States to make the list include:

  • No. 1 Ohio (including Cincinnati, Cleveland, and Columbus)
  • No. 2 Indiana (including Indianapolis)
  • No. 3 Florida (including Jacksonville and Miami-Fort Lauderdale)
  • No. 4 Georgia (including Atlanta and Augusta)
  • No. 5 Wisconsin (including Madison and Kenosha)

Regional state clusters to watch include:

  • Phoenix
  • Pittsburgh
  • Greater Richmond, Virginia
  • South Carolina
  • Utah

See the full report here.

Another pharma giant will build a massive manufacturing facility in Houston. Rendering courtesy Bristol Myers Squibb Co.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

Bristol Myers Squibb Co. is considering the Generation Park for a new $1 billion manufacturing campus. Rendering courtesy McCord

Pharma giant considers Houston for $1 billion manufacturing campus

in the works

Another pharmaceutical giant is considering Houston’s Generation Park for a manufacturing hub.

According to a recent filing with the Texas Jobs, Energy, Technology and Innovation (JETI) program, Bristol Myers Squibb Co. is considering the northeast Houston management district for a new $1 billion multi-modal pharmaceutical manufacturing campus.

If approved, the campus, known as Project Argonaut, could create 489 jobs in Texas by 2031. Jobs would include operations technicians, engineering roles, administrative and management roles, production specialists, maintenance support, and quality control/assurance. The company predicts annual average wages for these positions to be around $96,000, according to the filing.

The project currently includes the 600,000-square-foot facility, but according to the filing, Bristol Myers Squibb “envisions this site growing in scale and capability well beyond its opening configuration."

The Texas JETI program offers companies temporary school property tax limitations in exchange for major capital investment and job creation. E.R. Squibb & Sons LLC applied for a 10-year tax abatement agreement in the Sheldon Independent School District.

The agreement promises a $ 1 billion investment. Construction would begin in 2027 and wrap in 2029.

“The proposed project reflects [Bristol Myers Squibb Co.’s] enduring commitment to bringing innovative medicines to patients and ensuring the long-term supply reliability they depend on,” the filing says. “The proposed project is purpose-built to support and manufacture medicines spanning multiple therapeutic areas and modalities, positioning the site as a long-term launch and commercial campus for decades to come. These medicines will provide therapies to the [Bristol Myers Squibb Co.’s] patients located in markets both nationally and internationally.”

The Fortune 100 company is considering 16 other cities for the new manufacturing facility in the Central and Eastern markets in the U.S. According to the Houston Chronicle, Bristol Myers Squibb Co is still in the “evaluation process” for its potential manufacturing site.

Last fall, Eli Lilly and Co. selected Generation Park for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

MD Anderson receives $10M gift to launch pancreatic cancer program

med funding

The University of Texas MD Anderson Cancer Center will be getting a significant boost in the fight against pancreatic cancer thanks to a recent gift from longtime supporters Zelma and William Reid. The medical system announced this month that a $10 million donation would help it establish a new Pancreatic Cancer High-Risk Interception Program.

“Philanthropic investments like this create opportunities to accelerate discoveries and pursue bold approaches to some of the most challenging cancers we face,” said Dr. Jeffrey E. Lee, president ad interim of UT MD Anderson, said in a news release. “We are deeply grateful to Zelma and Bill Reid for their generosity and enduring commitment. Their support will help advance innovative research aimed at intercepting pancreatic cancer earlier, when we have the greatest opportunity to improve outcomes for patients.”

Pancreatic cancer is one of the most deadly types of cancer. Despite being relatively rare, it ranks third in total deaths from cancer in the United States. Less than 10 percent of patients diagnosed with pancreatic cancer are still alive five years later.

Dr. Florencia McAllister, William Reid, Dr. Michael P. Kim, Zelma Reid, Dr. Manoop S. Bhutani, and Dr. Matthew H.G. Katz. Photo courtesy MD Anderson

The problem is often detection. The pancreas is located deep in the upper abdomen among many other organs, which can make spotting tumors difficult. Some blood tests can indicate pancreatic cancer, but it is usually not diagnosed until it spreads.

The new Pancreatic Cancer High-Risk Interception Program hopes to assemble new diagnostic techniques and patient screening tools to increase early detection. MD Anderson’s Dr. Michael P. Kim, associate professor of surgical oncology; Dr. Manoop S. Bhutani, professor of gastroenterology and hepatology; and Dr. Florencia McAllister, professor of gastrointestinal medical oncology and genetics, will lead the new program.

The team will rely on advanced imaging, molecular diagnostics, AI-driven assessment, and DNA testing to both create an at-risk patient population profile and hopefully help detect the cancer in its earliest stages. For instance, some of these tools will be able to monitor pancreatic cysts without invasive surgery.

“The ultimate goal is to intercept pancreatic cancer development or to initiate treatment earlier in the disease process, when patients have the best chance for successful outcomes,” Kim added in the release. “This gift will allow us to expand our research efforts, strengthen collaborations across disciplines and accelerate promising strategies to identify and intercept pancreatic cancer before it becomes life-threatening. We are incredibly thankful to the Reids for making this work possible.”

Axiom Space inks partnership to grow semiconductor crystals in orbit

space deal

Down in Webster, Texas, and high above the Earth, Axiom Space and Kansas-based Nitride Global Inc. will grow the next generation of semiconductor crystals in microgravity thanks to a new memorandum of understanding (MOU) signed earlier this month.

“Signing this MOU with Nitride Global reflects the growing commercial interest in producing advanced semiconductor materials in space,” Lucie Low, chief science officer for Axiom Space, said in a news release. “Their leadership in aluminium nitride (AlN) crystal growth and advanced packaging technologies, combined with Axiom Space’s capabilities in orbital infrastructure and mission integration, position us to demonstrate real commercial value in low-Earth orbit (LEO).”

This latest partnership builds on existing collaboration between Axiom and NitrideGlobal and NASA Ames Research Center.

Aluminium nitride crystals are part of the cutting-edge generation of semiconductors essential to emerging high-voltage transistors and also used in various medical technologies. Because of their high thermal stability, they can be used in a variety of environments and applications that have revolutionized everything from electric cars to the grids the cars run on.

However, the crystals are challenging to grow on Earth and face defects and size limitations due to gravity. Growing them in space can enhance their performance, according to NitrideGlobal. Microgravity allows them to grow more uniformly and with fewer defects, potentially resulting in larger, purer and more reliable crystals.

That’s where Axiom Space comes in. The company is developing Axiom Station, a successor to the International Space Station, where new research and manufacturing can be carried out.

“This MOU marks a pivotal milestone in our close partnership with Axiom Space that started as part of the NASA Small Business Innovation Research (SBIR) for AlN growth in space and is now expanding to usher the development of an innovation ecosystem,” Mahyar Khosravi, CEO of Nitride Global Inc., added in the release. “With Axiom Space’s leadership in the in-space manufacturing sector, this partnership will aim to deliver a platform for commercially viable manufacturing of [ultrawide bandgap materials] that will enable the next generation of semiconductor & microelectronics for terrestrial and planetary exploration uses.”

Houston's IAH lands on list of 15 most expensive U.S. airports

Travel Woes

Hold on to those carry-on bags: George Bush Intercontinental Airport is checking in as one of the 15 most expensive airports in the U.S., a new study has revealed.

The analysis from digital commerce and marketing platform ConsumerVoice.org compared the average domestic flight costs at the 50 largest U.S. airports, ranking them from highest to lowest. Flight price data was sourced from the U.S. Department of Transportation’s Bureau of Transportation Statistics (BTS) during the first and second quarters of 2026 and compared with the same period in 2025.

Washington Dulles International Airport in Virginia tops the list as the priciest major airport in the U.S, with domestic flights at IAD costing $534.34 on average. Charlotte Douglas International Airport in North Carolina comes in second place with an average fare cost of $527.79.

IAH lands at No. 13 nationwide, and it's the second most expensive in Texas, the findings show. The typical domestic flight from IAH costs $482.02, and they aren't getting any cheaper. Flights out of IAH are nine percent more expensive than they were a year ago, the report found. The average domestic flight cost $37.80 less in 2025.

Houstonians not only need to be prepared to spend a little extra money when booking their tickets; they'll also need to pack their patience, as IAH also ranks among the worst airports for flight delays and cancellations.

Travelers on a budget can save more on flights out of William P. Hobby Airport, if they're willing to make the drive. Travelers can save about 13 percent on their flights by flying through HOU instead of IAH, but there are other costs to take into consideration.

"Ground transportation, gas, and parking can eat into the difference, so factor these in when choosing the most economical departure airport," the report said.

HOU ranked as the No. 31 most expensive airport on the list with domestic flights coming in at $417.78 on average. Average fares at HOU are also nine percent more expensive than they were last year.

The top 10 priciest major airports in the U.S. are:

  • No. 1 – Washington Dulles International Airport
  • No. 2 – Charlotte Douglas International Airport
  • No. 3 – Detroit metro Wayne County Airport
  • No. 4 – Salt Lake City International
  • No. 5 – Minneapolis-St. Paul International
  • No. 6 – San Francisco International
  • No. 7 – John F. Kennedy International
  • No. 8 – Newark Liberty International
  • No. 9 – Dallas/Fort Worth International
  • No. 10 – Hartsfield-Jackson Atlanta International
---

This article originally appeared on CultureMap.com.